These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 12550794

  • 1. In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases.
    Guggi D, Bernkop-Schnürch A.
    Int J Pharm; 2003 Feb 18; 252(1-2):187-96. PubMed ID: 12550794
    [Abstract] [Full Text] [Related]

  • 2. Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro.
    Marschütz MK, Bernkop-Schnürch A.
    Biomaterials; 2000 Jul 18; 21(14):1499-507. PubMed ID: 10872779
    [Abstract] [Full Text] [Related]

  • 3. Intestinal peptide and protein delivery: novel bioadhesive drug-carrier matrix shielding from enzymatic attack.
    Bernkop-Schnürch A, Pasta M.
    J Pharm Sci; 1998 Apr 18; 87(4):430-4. PubMed ID: 9548894
    [Abstract] [Full Text] [Related]

  • 4. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix.
    Guggi D, Kast CE, Bernkop-Schnürch A.
    Pharm Res; 2003 Dec 18; 20(12):1989-94. PubMed ID: 14725364
    [Abstract] [Full Text] [Related]

  • 5. Development and in vitro evaluation of a drug delivery system based on chitosan-EDTA BBI conjugate.
    Bernkop-Schnürch A, Krauland A, Valenta C.
    J Drug Target; 1998 Dec 18; 6(3):207-14. PubMed ID: 9888307
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and in vitro evaluation of chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery of peptides and proteins.
    Bernkop-Schnürch A, Scerbe-Saiko A.
    Pharm Res; 1998 Feb 18; 15(2):263-9. PubMed ID: 9523313
    [Abstract] [Full Text] [Related]

  • 7. Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery.
    Shah RB, Khan MA.
    J Pharm Sci; 2004 Feb 18; 93(2):392-406. PubMed ID: 14705196
    [Abstract] [Full Text] [Related]

  • 8. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin.
    Guggi D, Krauland AH, Bernkop-Schnürch A.
    J Control Release; 2003 Sep 19; 92(1-2):125-35. PubMed ID: 14499191
    [Abstract] [Full Text] [Related]

  • 9. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats.
    Krauland AH, Guggi D, Bernkop-Schnürch A.
    J Control Release; 2004 Mar 24; 95(3):547-55. PubMed ID: 15023465
    [Abstract] [Full Text] [Related]

  • 10. Chitosan-pentaglycine-phenylboronic acid conjugate: a potential colon-specific platform for calcitonin.
    Smoum R, Rubinstein A, Srebnik M.
    Bioconjug Chem; 2006 Mar 24; 17(4):1000-7. PubMed ID: 16848408
    [Abstract] [Full Text] [Related]

  • 11. Design and evaluation of a chitosan-aprotinin conjugate for the peroral delivery of therapeutic peptides and proteins susceptible to enzymatic degradation.
    Werle M, Loretz B, Entstrasser D, Föger F.
    J Drug Target; 2007 Jun 24; 15(5):327-33. PubMed ID: 17541841
    [Abstract] [Full Text] [Related]

  • 12. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems.
    Bernkop-Schnürch A.
    Int J Pharm; 2000 Jan 20; 194(1):1-13. PubMed ID: 10601680
    [Abstract] [Full Text] [Related]

  • 13. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates.
    Bernkop-Schnürch A, Krajicek ME.
    J Control Release; 1998 Jan 02; 50(1-3):215-23. PubMed ID: 9685888
    [Abstract] [Full Text] [Related]

  • 14. Effects of polyacrylic polymers on the degradation of insulin and peptide drugs by chymotrypsin and trypsin.
    Bai JP, Chang LL, Guo JH.
    J Pharm Pharmacol; 1996 Jan 02; 48(1):17-21. PubMed ID: 8722488
    [Abstract] [Full Text] [Related]

  • 15. Design and in vivo evaluation of an oral delivery system for insulin.
    Marschütz MK, Caliceti P, Bernkop-Schnürch A.
    Pharm Res; 2000 Dec 02; 17(12):1468-74. PubMed ID: 11303955
    [Abstract] [Full Text] [Related]

  • 16. Design and in vitro evaluation of a mucoadhesive oral delivery system for a model polypeptide antigen.
    Marschütz MK, Puttipipatkhachorn S, Bernkop-Schnürch A.
    Pharmazie; 2001 Sep 02; 56(9):724-9. PubMed ID: 11593993
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of a mixture of cyclic peptides based on the Bowman-Birk reactive site loop to screen for serine protease inhibitors.
    Domingo GJ, Leatherbarrow RJ, Freeman N, Patel S, Weir M.
    Int J Pept Protein Res; 1995 Jul 02; 46(1):79-87. PubMed ID: 7558601
    [Abstract] [Full Text] [Related]

  • 18. Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration.
    Werle M, Kafedjiiski K, Kolmar H, Bernkop-Schnürch A.
    Int J Pharm; 2007 Mar 06; 332(1-2):72-9. PubMed ID: 17070661
    [Abstract] [Full Text] [Related]

  • 19. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase.
    Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR.
    Arch Biochem Biophys; 1997 Aug 01; 344(1):133-8. PubMed ID: 9244390
    [Abstract] [Full Text] [Related]

  • 20. Proteinase inhibition using small Bowman-Birk-type structures.
    Fernandez JH, Mello MO, Galgaro L, Tanaka AS, Silva-Filho MC, Neshich G.
    Genet Mol Res; 2007 Oct 05; 6(4):846-58. PubMed ID: 18058707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.